Groundbreaking study unveils sex-specific genetic influences on blood pressure

Genetic heterogeneity of blood pressure (BP) effects between sexes.

J&J licenses LegoChem’s Trop2 ADC for $100M upfront

Johnson and Johnson’s subsidiary Janssen is licensing a Trop2 directed antibody-drug conjugate from South Korea’s LegoChem Biosciences in a deal that could be worth as

December 27, 2023

Roche’s $3 billion Alnylam deal shows drug firms are interested in long-acting heart drugs

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of

July 24, 2023

Drug delivery CDMO earmarks $356M to expand injectable device capacity

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.